This complementary agonism between ADP and HMGB1 furthers the understanding of thromboinflammatory signaling in conditions such as SCD, and provides insight for therapeutic P2Y12 inhibition. This evidence concerns the gene HMGB1 and Schnyder corneal dystrophy.